Autres langues Nykode Therapeutics

Actions

VACC

NO0010714785

Marché Fermé - Oslo Bors Autres places de cotation 16:45:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
12,98 ^NOK	+0,62 %		+0,15 %	-39,35 %

19/04	Nykode Therapeutics ASA lance un essai de phase 2 sur le VB10.16 dans le traitement de deuxième intention du cancer du col de l'utérus positif pour le HPV16	CI
21/03	Nykode Therapeutics annonce les conclusions principales confirmant les bénéfices cliniques prolongés des données de survie maturées de l'essai de phase 2 C-02 dans le cancer du col de l'utérus avancé	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	19/04
Nykode Therapeutics : Remuneration Report 2023	19/04
Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	19/04
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer	21/03
Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases	19/03
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Nykode Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer	14/12
Nykode Therapeutics AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider	27/10/23
Nykode Therapeutics AS announced that it has received NOK 505.29474 million in funding	25/10/23
Nykode Therapeutics AS announced that it expects to receive NOK 329.999987 million in funding	24/10/23
Nykode Therapeutics Kicks off Early-stage Trial of Head, Neck Skin Cancer Treatment	29/09/23
Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer	29/09/23
Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research	20/09/23
Nykode Therapeutics Wins US FDA Nod for Mid-stage Study of Cervical Cancer Combo	05/09/23
Nykode Therapeutics ASA Announces FDA Approval of IND for VB-C-04, a Trial of VB-C-04 in HPV16-Positive Cervical Cancer	05/09/23
Nykode Therapeutics : 2Q 2023 Financial Results – presentation	23/08/23
Nykode Therapeutics AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23/08/23
Nykode Therapeutics : ABGSC Life Science Summit 30-31 May 2023 – presentation	07/06/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Nykode Therapeutics

Actions

VACC

NO0010714785

Autres langues

Filtres